Author Response: Clinical Significance of Anti-NMDAR Concurrent With Glial or Neuronal Surface Antibodies

Affiliations

Comment

Josep Dalmau et al. Neurology. 2021.

. 2021 Jan 26;96(4):188-189.

doi: 10.1212/WNL.0000000000011359.

No abstract available

Comment on

Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies.
Martinez-Hernandez E, Guasp M, García-Serra A, Maudes E, Ariño H, Sepulveda M, Armangué T, Ramos AP, Ben-Hur T, Iizuka T, Saiz A, Graus F, Dalmau J. Martinez-Hernandez E, et al. Neurology. 2020 Jun 2;94(22):e2302-e2310. doi: 10.1212/WNL.0000000000009239. Epub 2020 Mar 11. Neurology. 2020. PMID: 32161029
Reader Response: Clinical Significance of Anti-NMDAR Concurrent With Glial or Neuronal Surface Antibodies.
Lancaster E. Lancaster E. Neurology. 2021 Jan 26;96(4):185-186. doi: 10.1212/WNL.0000000000011361. Neurology. 2021. PMID: 33495393 No abstract available.
Reader Response: Clinical Significance of Anti-NMDAR Concurrent With Glial or Neuronal Surface Antibodies.
McKeon A, Dubey D, Flanagan EP, Pittock SJ, Zekeridou A. McKeon A, et al. Neurology. 2021 Jan 26;96(4):186-188. doi: 10.1212/WNL.0000000000011362. Neurology. 2021. PMID: 33495394 No abstract available.